Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)
(2014) In British Journal of Dermatology 171(6). p.1318-1325- Abstract
- This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should... (More)
- This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5081895
- author
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Dermatology
- volume
- 171
- issue
- 6
- pages
- 1318 - 1325
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000347236100172
- scopus:84908096132
- pmid:24980543
- ISSN
- 1365-2133
- DOI
- 10.1111/bjd.13237
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Dermatology and Venerology (013241320), Department of Dermatology and Venereology (Lund) (013006000)
- id
- 03f47d13-3264-4277-bbd1-192794b8b744 (old id 5081895)
- date added to LUP
- 2016-04-01 10:11:12
- date last changed
- 2025-04-04 13:57:36
@article{03f47d13-3264-4277-bbd1-192794b8b744,
abstract = {{This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure.}},
author = {{Chalmers, J. R. and Schmitt, J. and Apfelbacher, C. and Dohil, M. and Eichenfield, L. F. and Simpson, E. L. and Singh, J. and Spuls, P. and Thomas, K. S. and Admani, S. and Aoki, V. and Ardeleanu, M. and Barbarot, S. and Berger, T. and Bergman, J. N. and Block, J. and Borok, N. and Burton, T. and Chamlin, S. L. and Deckert, S. and DeKlotz, C. C. and Graff, L. B. and Hanifin, J. M. and Hebert, A. A. and Humphreys, R. and Katoh, N. and Kisa, R. M. and Margolis, D. J. and Merhand, S. and Minnillo, R. and Mizutani, H. and Nankervis, H. and Ohya, Y. and Rodgers, P. and Schram, M. E. and Stalder, J. F. and Svensson, Åke and Takaoka, R. and Teper, A. and Tom, W. L. and von Kobyletzki, Laura and Weisshaar, E. and Zelt, S. and Williams, H. C.}},
issn = {{1365-2133}},
language = {{eng}},
number = {{6}},
pages = {{1318--1325}},
publisher = {{Wiley-Blackwell}},
series = {{British Journal of Dermatology}},
title = {{Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)}},
url = {{https://lup.lub.lu.se/search/files/1635251/7761923}},
doi = {{10.1111/bjd.13237}},
volume = {{171}},
year = {{2014}},
}